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Introduction
Recipients of allogeneic hematopoietic stem cell trans-
plantation (HSCT) suffer from a prolonged posttrans-
plant immune deficiency that results in significant
morbidity and mortality from infections (1–3). This
immune deficiency is most pronounced in the T cell
lineage due to a severe delay in T cell reconstitution.
Reconstitution of CD4+ T cells in particular is severely
impaired in adult recipients, and the rate of recovery of
CD4+ T cells is inversely related to the age of the recip-
ient and correlates with the risk of developing infec-
tions (3–5). Posttransplant T cell recovery is affected by
a number of factors, including previous chemo/radia-
tion therapy, a lack of sustained transfer of donor
immunity, recapitulation of immunological ontology,
age of the recipient, infections, thymic involution after
puberty, donor/host histoincompatibility, graft-versus-
host disease (GVHD), graft rejection, and drug-induced
immunosuppression such as from antibiotics or
GVHD prophylaxis (reviewed in ref. 6). 
Prolonged T cell deficiency after transplant contin-
ues even after quantitative regeneration has taken
place, suggesting that a T cell dysfunction occurs in the
posttransplant period that is still poorly understood
(7–10). This impaired T cell immunity is at least par-
tially explained by the limited diversity of the post-
transplant T cell receptor (TCR) repertoire (11).
Posttransplant T cell reconstitution involves thymus-
dependent de novo T cell generation, extrathymic
expansion of mature T cells that were transferred with
the allograft, and possibly de novo T cell generation
from extrathymic sites such as mucosa-associated lym-
phoid tissues in the gut (12). Previous studies in mice
and humans have suggested that T cell reconstitution
in older recipients is more dependent on extrathymic
expansion of mature T cells than on thymopoiesis; this
conclusion was based upon the delayed reappearance of
naive T cells (especially CD4+ T cells) and a diminished
T cell repertoire (13–18).
The size of the peripheral T cell pool can rapidly
expand and contract during an antigen-specific
immune response, but remains remarkably constant
throughout life due to tight regulation by a number
of cytokines (especially IL-7 and IL-15), and in the
case of naive T cells, the interaction of the TCR with
self-peptide–MHC ligands (reviewed in ref. 19).
Homeostatic expansion/proliferation is an important
regulatory mechanism of T cell homeostasis and is
defined as the proliferative response of mature T cells
in a lymphopenic environment. Naive T cells convert
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to a memory-like phenotype and require IL-7 and
TCR recognition during homeostatic proliferation.
IL-7 is a γ-common chain cytokine, which is secreted
by stromal cells in bone marrow (BM) and thymus and
plays an important role in the development, survival,
and homeostatic proliferation of T cells (19–22).
In this study, we examined the contribution of home-
ostatic proliferation, which is associated with the
acquisition of a memory-like phenotype, to T cell
reconstitution in recipients of allogeneic HSCT. Our
data suggest that in addition to mature T cells (trans-
ferred in the allograft), de novo–generated T cells
(derived from donor hematopoietic precursor cells)
also undergo homeostatic proliferation in the lym-
phopenic posttransplant environment of the recipient.
We found that posttransplant IL-7 administration pro-
motes T cell reconstitution not only through its effects
on thymopoiesis (as we have previously shown, as
described in ref. 23), but also by stimulating homeo-
static proliferation of nonalloreactive donor T cells
(either de novo–generated or transferred with the allo-
graft) and antiapoptotic effects on peripheral T cells.
Methods
Mice and BM transplantation. Female C57BL/6 (B6, H-2b),
C3FeB6F1 (H-2b/k), B6D2F1/J (H-2b/d), B10.BR (H-2k),
CBA/J (H-2k), and C57BL/6 (Ly5.1+) mice were obtained
from The Jackson Laboratory (Bar Harbor, Maine,
USA). For some experiments, C57BL/6 (Ly5.1+) mice
were obtained from the National Cancer Institute (Fred-
erick, Maryland, USA). Mice used in BM transplanta-
tion (BMT) experiments were between 8 weeks and 10
weeks of age or were 9 months (CBA/J) of age. BMT pro-
tocols were approved by the Memorial Sloan-Kettering
Cancer Center Institutional Animal Care and Use Com-
mittee. BM cells were removed aseptically from femurs
and tibias. Donor BM was T cell depleted (TCD) by
incubation with anti–Thy-1.2 for 30 minutes at 4°C, fol-
lowed by incubation with Low-TOX-M rabbit comple-
ment (Cedarlane Laboratories Ltd., Hornby, Ontario,
Canada) for 40 minutes at 37°C. Splenic T cells were
obtained either by purification over a nylon wool col-
umn, by positive selection with anti-CD5 antibodies
conjugated to magnetic beads (Miltenyi Biotec, Auburn,
California, USA), or by negative selection using lineage-
specific antibodies (NK1.1, Gr-1, Mac-1, B220) conju-
gated to FITC or phycoerythrin (PE) followed by anti-
FITC or anti-PE antibodies coupled to magnetic beads
(Miltenyi Biotec). Cells (5 × 106 to 10 × 106 BM cells with
or without splenic T cells) were resuspended in DMEM
(Life Technologies, Grand Island, New York, USA) and
transplanted by tail vein infusion (0.25 ml total volume)
into lethally irradiated recipients on day 0. On day 0,
prior to transplantation, recipients received 1,300 cGy
total body irradiation (137Cs source) as a split dose with
a 3-hour interval between doses (to reduce gastroin-
testinal toxicity). Mice were housed in sterilized
microisolator cages and received normal chow and
autoclaved hyperchlorinated drinking water (pH 3.0).
Reagents and antibodies. Anti-murine CD16/CD32 FcR
block (2.4G2) and all of the following fluorochrome-
labeled antibodies against murine antigens were
obtained from BD PharMingen (San Diego, California,
USA): Ly9.1 (30C7), CD3 (145-2C11), CD4 (RM4-5),
CD8 (53-6.7), CD62L (MEL-14), CD122 (TM-B1),
CD44 (IM7), CD45R/B220 (RA3-6B2), NK1.1 (PK136),
CD11b (M1/70), CD25 (PC61), CD127 (B12-1), CD69
(H1.2F3), c-kit (2B8), SCA-1 (D7), Bcl-2 (3F11), annex-
in V, the BrdU detection kit, 7-amino-actinomycin D 
(7-AAD), isotypic controls, rat IgG2a,κ (R35-95), rat
IgG2a,λ (B39-4), rat IgG2b,κ (A95-1), rat IgG1,κ (R3-34),
hamster IgG1,κ (A19-3), and hamster IgG2,λ (Ha4/8).
Streptavidin-FITC, -PE, and –peridinin chlorophyll pro-
tein were also obtained from BD PharMingen. Recom-
binant human IL-7 was kindly provided by Michel
Morre (Cytheris, Vanves, France). CFSE was obtained
from Molecular Probes Inc. (Eugene, Oregon, USA).
BrdU (Sigma-Aldrich, St. Louis, Missouri, USA) and
deoxyribonuclease I (DN-25; Sigma-Aldrich) were used
in BrdU and cell cycling studies.
Tissue culture medium consisted of RPMI 1640 sup-
plemented with 10% heat-inactivated FCS, 100 U/ml peni-
cillin, 100 µg/ml streptomycin, and 2 mM L-glutamine.
Administration of BrdU. Recipients of allogeneic BMT
received BrdU (0.8 mg/ml) from day 15 to day 33 after
transplant in their drinking water, which was prepared
fresh daily and protected from light.
Administration of IL-7. For immune reconstitution
studies, IL-7 was given from day 21 to day 27 (10
µg/day intraperitoneally). For GVHD studies, IL-7 was
administered on days 0–7 (10 µg/day intraperitoneal-
ly). In adoptive transfer experiments with CFSE-labeled
T cells, IL-7 was administered at a dose of 10 µg/day
intraperitoneally from day 0 to day 3.
Purified stem cell preparation. BM cells from donor mice
were obtained as described above. Lineage-negative cells
were obtained by magnetic bead cell separation using
lineage-specific antibodies against CD3, NK1.1, Gr-1,
Mac-1, B220, CD4, and CD8. These lineage-negative cells
were incubated with antibodies against SCA-1 and c-kit,
and then lineage-negative SCA-1+ and c-kit+ cells were
obtained by flow cytometric–assisted cell sorting
(MoFlo; Cytomation Inc., Fort Collins, Colorado, USA)
as previously described (24).
Assessment of GVHD. The severity of GVHD was
assessed with a clinical GVHD scoring system as previ-
ously described (25). Briefly, ear-tagged animals in
coded cages were individually scored every week for five
clinical parameters on a scale from 0 to 2: weight loss,
posture, activity, fur, and skin. A clinical GVHD index
was generated by summation of the five criteria scores
to give a total score of 0–10. Survival was monitored
daily. Animals with scores of 5 or higher were consid-
ered moribund and were sacrificed.
Cells. As described before, splenic T cells were obtained
by purification over a nylon wool column, which resulted
in greater than 70% purity. Single-cell suspensions were
prepared from inguinal and axillary lymph nodes and
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spleens according to standard protocols and used for flow
cytometric analysis. Intraepithelial lymphocytes from gut
were obtained as published previously (26). Briefly, mesen-
teric tissues were removed from intestines that were then
cut longitudinally, washed with PBS, and put into 250-ml
cell culture flasks. Segments of intestines were incubated
with RPMI with 10% FCS for 1 hour at 37°C in a shaker.
Finally, cells released from the intestine into the medium
were obtained using either a nylon wool column or Percoll
gradient separation. Single-cell suspensions of liver cells
were obtained by Percoll gradient separation.
CFSE labeling. Cells were labeled with CFSE as
described previously (27). Briefly, cells (thymocytes or
splenocytes) were incubated with CFSE at a final con-
centration of 2.5 µM in HBSS at 37°C for 10 minutes.
Cells were then washed three times with HBSS before
intravenous injection.
Flow cytometric analysis. Cells were washed in FACS
buffer (PBS with 0.5% BSA and 0.1% sodium azide), and
106 cells/ml were incubated for 30 minutes at 4°C with
CD16/CD32 FcR block. Subsequently, cells were incu-
bated for 30 minutes at 4°C with antibodies and washed
twice with FACS buffer. The stained cells were resus-
pended in FACS buffer and analyzed on a FACScan flow
cytometer (Becton, Dickinson and Co., San Jose, Cali-
fornia, USA) with CellQuest software or with FlowJo
software (Tree Star Inc., San Carlos, California, USA).
Intracellular staining. Cells were incubated for 5 hours
with 10 ng/ml PMA and 2 µM ionomycin. Brefeldin A
(10 µg/ml) was added after 2 hours of incubation. The
cells were then harvested, washed, and stained with flu-
orochrome-conjugated antibodies against cell surface
antigens. Subsequently, cells were fixed and permeabi-
lized with Cytofix/Cytoperm Kit reagents (BD PharMin-
gen) and stained with PE-conjugated antibodies.
BrdU and 7-AAD staining for cell proliferation. Single-cell
suspensions of spleens were obtained from allogeneic
BMT recipients at day 28 or day 33. Cells were stained with
fluorochrome-conjugated antibodies against cell surface
antigens. The cells were then washed, fixed, permeabilized,
and refixed according to manufacturer protocol using the
BrdU Flow Kit (BD PharMingen). Fixed cells were incu-
bated with DNase for 1 hour at 37°C and then washed
and stained with anti-BrdU antibody or 7-AAD. Finally,
flow cytometric analysis was conducted by gating for the
designated populations and the FL3 fluorescence detec-
tor was used in linear mode for 7-AAD analysis.
Proliferation assay. Splenocytes (5 × 104 cells/well; pre-
pared as described above) were incubated for 5 days
with irradiated (2,000 cGy) C3FeB6F1 splenocytes as
stimulators (2 × 105 cells/well) in 96-well plates. Cul-
tures were pulsed during the final 18 hours with 1
microcurie/well 3H-thymidine and cells were harvest-
ed with a Topcount Harvester (Packard Bioscience Co.,
Meriden, Connecticut, USA).
Statistics. All values are expressed as mean ± SEM.
Statistical comparison of experimental data was per-
formed with the nonparametric unpaired Mann-
Whitney U test, whereas the Mantel-Cox log rank test
was used for survival data. A P value below 0.05 was
considered statistically significant.
Results
T cell reconstitution is delayed after allogeneic BMT. To study
peripheral T cell reconstitution after allogeneic HSCT
and the effects of IL-7, we used well-described clinical-
ly relevant MHC-matched and -mismatched murine
allogeneic BMT models. First, we analyzed the donor-
derived immune reconstitution after a TCD allogeneic
BMT (in which case no GVHD occurs) or an allogene-
ic BMT with GVHD in an MHC-matched model with a
disparity in minor histocompatibility antigens: B10.BR
→ CBA/J (23, 28, 29). GVHD was induced by the addi-
tion of donor splenic T cells to the allograft. We chose
this model because of its clinical relevance for and
resemblance to patients receiving an allogeneic HSCT
from an MHC-matched unrelated donor. These
patients suffer from a profound and prolonged post-
transplant immune deficiency associated with high
mortality from infections, which is in most studies
even higher than mortality from relapse (2, 30–34).
Donor-derived T cell reconstitution was severely
delayed, and even at 3 months after BMT the numbers
of CD3+, CD4+, and CD8+ T cells had not reached the lev-
els found in normal host or donor mice (Figure 1a). Sim-
ilar to T cell reconstitution in allogeneic HSCT patients
(3), early CD4+ T cell reconstitution was slower than
CD8+ T cell reconstitution, and the CD4/CD8 ratio was
decreased during the first 6 weeks after transplant (data
not shown). Donor-derived T cell reconstitution in recip-
ients with GVHD remained severely suppressed until the
mice died; this is reminiscent of the severe immunosup-
pression found in patients with GVHD (35).
In contrast to the severely suppressed B cell reconsti-
tution in recipients with GVHD, the numbers of donor-
derived B cells in allogeneic TCD-BMT recipients
reached the levels of those in nontransplanted host ani-
mals by 6 weeks after transplant (Figure 1b). Numbers
of CD11b+ monocytes and granulocytes in the spleen of
allogeneic TCD-BMT recipients were three- to fourfold
higher than in normal donor and host animals in the
first 2 weeks after transplant, and normalized by 6 weeks
after transplant (data not shown). This early increase in
CD11b+ cells is probably be due to granulopoiesis in the
spleen during the first weeks after transplant. Interest-
ingly, recipients with GVHD also had high numbers of
CD11b+ cells, which had not decreased by 6 weeks after
transplant when all animals had died from GVHD.
Finally, NK reconstitution was rapid, and numbers of
donor-derived NK cells reached the levels of normal
donor and host animals by 4 weeks (data not shown).
Posttransplant administration of IL-7 increases donor-derived
memory-like CD44high T cells. In addition to the profound
delay in T cell reconstitution, we noted that most donor-
derived CD4+ and CD8+ T cells had a memory-like
CD44high phenotype at day 28 after an allogeneic TCD-
BMT (Figure 1c). In our previously published experi-
ments, we did not observe any difference in T cell recovery
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in the thymus or periphery between IL-7–treated and
control groups when IL-7 was administered from day 0
to day 14 after BMT (23). However, we found increased
immune reconstitution after IL-7 administration from
day 14 to day 28 (continuous by subcutaneous pump) or
from day 21 to day 27 (intraperitoneally). Therefore, we
treated recipients from day 21 to day 28 after BMT with
IL-7. Because IL-7 administration could stimulate early
lymphoid precursors, which can express IL-7R (36) and
need 15–18 days to differentiate into naive T cells (37),
we measured donor-derived naive and memory T cell
populations at varying times after transplant. This also
allowed us to assess the duration of the IL-7–induced
increase in T cell numbers after discontinuation of IL-7
administration. We detected no increase in naive CD4+
T cells and only a small (but significant) increase in naive
CD8+ T cells at day 28 after transplant (Figure 1d). In
contrast, memory-like CD4+ and CD8+ T cells in IL-7–
treated recipients were significantly increased, and
donor-derived memory-like CD4+ T cells on day 28
reached even higher levels than in normal animals.
Nonalloreactive donor T cells undergo homeostatic prolifer-
ation upon transfer to lethally irradiated allogeneic recipients.
To better understand the preferential effect of IL-7 on
the posttransplant reconstitution of memory/activat-
ed T cells, we first analyzed the phenotype and prolif-
eration of the various populations of donor T cells after
allogeneic BMT, including (a) alloreactive T cells,
mature T cells contained in the allograft that recognize
host allo-antigens and cause GVHD; (b) nonalloreac-
tive T cells, mature T cells in the allograft that do not
recognize alloantigens but have been suggested to con-
Figure 1
T cell and B cell reconstitution after allogeneic BMT. (a and b) Lethally irradiated (1,300 cGy) CBA/J recipients were transplanted with B10.BR
TCD-BM (5 × 106) with or without B10.BR T cells (0.5 × 106) to induce GVHD. At different timepoints after BMT, animals were sacrificed
and absolute numbers of donor-derived cell populations in the spleen were calculated from total cell counts and multicolor flow cytomet-
ric analyses of T cells with anti-CD3, -CD4, and -CD8 antibodies (a), and B cells with anti-B220 antibody (b). Donor or host origin was
determined with anti-Ly9.1, which is present on host leukocytes. Allo, allogeneic. (c) The dot plots demonstrate how CD44high and CD44low
T cells can be distinguished by flow cytometric analysis in the spleen of a normal mouse and that CD44low populations represent naive CD4+
T cells, which express CD62L, or naive CD8+ T cells, which do not express CD122. CBA/J mice were transplanted as described in Figure 1a
without the addition of T cells, and splenocytes were analyzed on day 28. Naive CD4 cells were defined as CD4+CD44low, memory/activat-
ed (MEM/ACT) CD4 cells were defined as CD4+CD44high, naive CD8 cells were defined as CD8+CD44low, and memory/activated CD8 cells
were defined as CD8+CD44high. (d) CBA/J mice were transplanted as described in Figure 1a without the addition of T cells and received 10
µg/day IL-7 or PBS (control) on days 21–27 by intraperitoneal injection. Splenocytes were analyzed at different timepoints after transplant.
Values represent the mean cell number ± SEM (n = 6–20). *P < 0.05.
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tribute to T cell reconstitution, especially in older recip-
ients with diminished thymic function (17); and (c)
donor hematopoietic stem cell–derived T cells, newly
derived T cells that originate from the transplanted
donor hematopoietic stem cells and have been gener-
ated through thymic (and possibly also through
extrathymic) differentiation.
To assess the proliferative activity and cell surface anti-
gen expression patterns of alloreactive and nonalloreac-
tive donor T cells after transplantation, we transferred
CFSE-labeled purified splenic T cells from B6 (Ly5.1)
donors into lethally irradiated syngeneic (B6) and allo-
geneic (C3FeB6F1) recipients and analyzed the number
of cell divisions and cell surface antigen expression daily
for 7 days (Figure 2a, 64 hours, and data not shown).
When transferred into a lethally irradiated syngeneic recip-
ient, B6 (Ly5.1) T cells undergo not more than three cell
cycles in 64 hours, which is in agreement with the slow
proliferation described previously for homeostatic pro-
liferation of mature T cells in lymphopenic hosts (38–42).
These T cells acquire a partially activated memory-
like cell surface expression pattern during their home-
ostatic proliferation, consisting of increased expression
of CD44 and CD122. However, CD62L was downregu-
Figure 2
Alloreactive and nonalloreactive donor T cells can be distinguished by their phenotype and proliferation kinetics. (a and b) Lethally irradi-
ated (1,300 cGy) C3FeB6F1 (allogeneic, Allo) or B6 (syngeneic, Syn) recipients were transplanted with B6 BM (5 × 106) and CFSE-labeled
B6 (Ly5.1+) purified T cells (2 × 107). At various timepoints after BMT, recipients were sacrificed and splenocytes were stained with anti-
CD8, -CD25, -CD44, -CD62L, and -CD122 antibodies. Flow cytometric analysis is shown for expression of these antibodies on donor CD8+
T cells 64 hours after BMT (a).CD69 expression on donor CD4 and CD8 T cells in the spleen was determined 16 hours, 40 hours, and 64
hours after BMT (b). (c) Lethally irradiated (750 cGy) B6D2F1/J recipients were transplanted with CFSE-labeled B6 purified T cells (2 × 107).
After 64 hours, mice were sacrificed, splenocytes were stained with anti-CD4 and -CD8 antibodies, and FSC intensity was determined. A:
nondividing cells; B: slow proliferating cells; C: fast proliferating cells. FSC, forward scatter; % of max, % of maximum number of the cells
per group. (d) Lethally irradiated (750 cGy) C3FeB6F1 recipients were transplanted with CFSE-labeled B6 purified T cells (2 × 107). After 64
hours, mice were sacrificed and splenocytes were sorted according to CFSE intensity, shown in a histogram plot as fast- and slow-prolifer-
ative cells. Cells were incubated with irradiated C3FeB6F1 splenocytes as stimulators for 5 days. IL-2 (20 IU/ml) was added after 72 hours,
and proliferation was determined by 3H-thymidine incorporation.
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lated on less than 40% of the cells and CD25 expression
was not increased.
CFSE-labeled T cells transferred into lethally irradi-
ated allogeneic recipients could be separated into two
populations of cells based upon their proliferation and
cell surface expression. The first population consisted
of cells that had undergone more than seven cell cycles
in 64 hours and acquired a fully activated cell surface
expression pattern with increased expression of CD44,
CD122, and CD25, and decreased expression of
CD62L. Based upon their rapid proliferation with a cell
cycle duration of 6–9 hours and their acquisition of an
activated cell surface antigen pattern, which is identi-
cal to the antigen-driven rapid proliferative response of
alloreactive T cells described previously (43, 44), we
conclude that these cells represent alloreactive T cells
that respond to host antigens.
The second population of T cells has slower prolifer-
ative kinetics (not more than three cell cycles in 64
hours) similar to those of T cells transferred into syn-
geneic hosts. These slowly proliferating T cells in allo-
geneic recipients acquire a cell surface expression pat-
tern similar to that of T cells transferred into syngeneic
recipients: increased CD44 and CD122 expression, but
only limited downregulation of CD62L and no increase
of CD25 expression. Based upon their similarity in pro-
Figure 3
IL-7Rα expression is downregulated on alloreactive T cells and IL-7 does not exacerbate the development of GVHD. (a) Lethally irradiated
(1,300 cGy) CBA recipients were transplanted with B10.BR TCD-BM. IL-7 (10 µg/day) or PBS (control) was administered by intraperitoneal
injection on days 21–27 after allogeneic BMT. Animals were sacrificed on day 28 and IL-7Rα expression was determined on donor-derived
splenic CD4+ and CD8+ cells in IL-7–treated, PBS (control), and age-matched nontransplanted mice by flow cytometric analysis. Naive and
memory/activated cells and donor/host origin were defined as in Figure 1. Iso-Ig, isotype control for the anti–IL-7Rα antibody. (b and c)
BMT was performed as described in Figure 2a. Spleens were harvested from mice at 16 hours and on day 7, and stained with anti-CD8 and
–IL-7Rα antibodies. (d) Sublethally irradiated (750 cGy) C3FeB6F1 recipients were infused with CFSE-labeled B6 purified T cells (2 × 107).
Spleen and superficial lymph nodes (axillary and inguinal) were harvested at day 3 and cells underwent flow cytometric analysis with anti-
CD8 and –IL-7Rα antibodies to determine the number of cell divisions and IL-7Rα expression of CD8+ T cells. (e) Lethally irradiated (1,300
cGy) CBA mice were transplanted with B10.BR TCD-BM (5 × 106) with T cells (0.5 × 106). Mice were sacrificed at day 7 or day 14 after BMT.
Spleen, gut, liver, and lymph nodes were harvested and mononuclear cells were obtained. Cells were stained with anti-CD4, -CD8, and –IL-7Rα
antibodies for flow cytometric analysis. Representative histograms of four mice are shown. Dotted lines indicate isotype control for IL-7Rα.
(f) Lethally irradiated (1,300 cGy) CBA mice were transplanted with B10.BR TCD-BM (5 × 106) and varying T cell doses: 0.5 × 106 (left
graph), 0.2 × 106 (right graph, circles), and 0.1 × 106 (right graph, diamonds). IL-7 (10 µg/day) or PBS (control) was administered by
intraperitoneal injection from day 0 to day 7 after allogeneic BMT. Open symbols represent the PBS (control) groups, and filled symbols
represent the IL-7–treated groups. Kaplan-Meier survival curves are shown (n = 8–24).
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liferation kinetics and cell surface expression pattern,
we conclude that these cells represent nonalloreactive
T cells undergoing homeostatic proliferation.
We also assessed the expression of the early activation
antigen CD69, and found increased expression on
CD4+ and CD8+ T cells transferred to syngeneic or allo-
geneic recipients at 16 hours; this increase disappeared
by the 40-hour timepoint (Figure 2b).
The differences in activation state between nonpro-
liferating, nonalloreactive T cells and alloreactive T
cells are further illustrated by differences in cell size as
determined by flow cytometry (Figure 2c). Alloreactive
T cells have a larger, blast-like size than nonalloreactive
proliferating T cells, which are only slightly larger than
nonproliferating T cells.
To further define the functional differences between the
fast-dividing alloreactive and slow-dividing nonalloreac-
tive T cells, we purified fast-proliferative and slow-prolif-
erative T cells from recipients of allogeneic CFSE-labeled
T cells by flow cytometry and incubated these popula-
tions with irradiated host cells for 5 days. We found that
alloreactive fast-dividing T cells had a significantly greater
proliferative response to host antigen than did the slow-
er-dividing nonalloreactive T cells (Figure 2d).
IL-7R is downregulated in alloreactive donor T cells. To assess
the sensitivity of these nonalloreactive and alloreactive T
cells to IL-7 administration, we analyzed the expression
of the IL-7 receptor α chain (IL-7Rα, CD127). We found
that most naive CD44low and memory/activated CD44high
CD4+ and CD8+ T cells in normal mice expressed IL-7R
(Figure 3a). We then analyzed the IL-7Rα expression on
these same populations of naive and memory/activated
T cells in recipients of allogeneic TCD-BMT (which incur
no GVHD) and found IL-7Rα expression on the majori-
ty of cells even in recipients treated with IL-7.
We also analyzed IL-7Rα expression on CFSE-labeled
donor T cells transferred to syngeneic or allogeneic recip-
ients and found intact IL-7Rα expression on homeosta-
tically proliferating T cells in syngeneic or allogeneic
recipients even after more than five cell cycles (Figure 3,
b and c). When we analyzed CFSE-labeled purified T cells
16 hours after injection into lethally irradiated recipi-
ents, we observed a decrease in IL-7Rα expression on
donor T cells transplanted into allogeneic recipients
compared with syngeneic recipients: 51% versus 83% for
CD4+ T cells and 58% versus 86% for CD8+ T cells (data
not shown and Figure 3b). Moreover, alloreactive T cells
that had gone through more than eight cell divisions in
7 days, expressed low levels of IL-7Rα (Figure 3c). When
we compared the proliferation and IL-7Rα expression on
CFSE-labeled T cells in the lymph nodes and the spleen
3 days after infusion, we noted only a small fraction of
fast-proliferating alloreactive T cells in the lymph nodes
compared with the spleen (Figure 3d). In recipients with
clinical GVHD, IL-7Rα expression on T cells in the tar-
get organs of GVHD (such as gut and liver) was evaluat-
ed, and donor-derived TCR-αβ+ intraepithelial lympho-
cytes in the gut and T cells in the liver were found to have
downregulated their IL-7Rα expression on day 7 (gut) or
day 14 (spleen, lymph node, and liver) (Figure 3e).
These data suggest that alloreactive T cells are not sen-
sitive to IL-7 and therefore that IL-7 administration
should have no (or little) effect on the development of
GVHD. We have previously published that IL-7 admin-
istration had no effect on GVHD mortality in two dif-
ferent GVHD models. However, a recent study showed
increased GVHD mortality in IL-7–treated recipients
(45). The authors suggested that the difference could be
due to the fact that in our previous study all experimen-
tal groups had high mortality (75–100%) from GVHD,
which could impair the sensitivity to find smaller differ-
ences in GVHD mortality between groups. Therefore, we
studied GVHD mortality in recipients of varying doses
of T cells, but could still not detect a significant increase
in GVHD mortality between IL-7–treated and control
groups, even when GVHD mortality was only 50% after
more than 100 days (Figure 3f).
Donor-derived peripheral T cells in recipients of puri-
fied allogeneic hematopoietic stem cells have predomi-
nantly a memory-like phenotype. As stated before, pre-
vious studies have suggested that the predominance of
T cells with a memory/activated phenotype after allo-
geneic BMT is due to the homeostatic expansion of non-
alloreactive mature T cells, which are transferred with
the allograft. However, in our experiments with TCD
allografts (Figure 1c), we noted that in the first weeks
after transplant, donor CD4+ and CD8+ T cells are most-
ly of a memory/activated phenotype. To rule out that
this early reconstitution of memory/activated T cells was
due to homeostatic expansion of a few contaminating
mature nonalloreactive donor T cells that had escaped
the T cell depletion, we repeated our T cell reconstitution
Figure 4
Most de novo–generated T cells after allogeneic BMT with purified
hematopoietic stem cells have a memory/activated phenotype.
Lethally irradiated (1,300 cGy) CBA/J mice were transplanted with
either B10.BR TCD-BM (allogeneic BMT) or lineage-negative SCA-1+c-
kit+ B10.BR BM cells (2 × 104). IL-7 (10 µg/day) or PBS (control) was
administered by intraperitoneal injection from day 21 to day 28 after
allogeneic BMT, and from day 28 to day 35 after allogeneic SCT. Ani-
mals were sacrificed and harvested on day 28 (BMT) and day 35
(SCT). Absolute numbers of specific donor-derived cell populations
were calculated from total cell counts and percentages of T cells by
flow cytometric analysis. Naive CD4+ T cells were defined as
CD44lowCD62Lhigh, activated CD4+ T cells as CD44highCD62Lhigh,
memory CD4+ T cells as CD44highCD62Llow, naive CD8+ T cells as
CD44low, and memory/activated CD8+ T cells as CD44high. Values
represent the mean cell number ± SEM (SCT: n = 3; BMT: n = 16).
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experiments with highly purified allogeneic lineage-neg-
ative SCA-1+c-kit+ hematopoietic stem cells (Figure 4). At
day 28 after transplant we again found a predominance
of memory/activated CD4+ and CD8+ T cells. IL-7
administration to recipients of allogeneic hematopoiet-
ic stem cells resulted not only in enhanced donor T cell
reconstitution, but also significantly increased naive
donor CD4+ and CD8+ T cells. We conclude from these
reconstitution experiments with purified allogeneic
hematopoietic stem cells that early T cell reconstitution
with mostly memory/activated T cells can also occur in
the absence of mature nonalloreactive donor T cells.
Thymocytes can undergo homeostatic proliferation upon
transfer in lethally irradiated syngeneic or allogeneic recipients.
To explain the predominance of memory-like T cells in
recipients of allogeneic hematopoietic stem cells, we
hypothesized that recent thymic emigrants (RTEs) with
a naive phenotype in the lymphopenic environment of
an allogeneic recipient will undergo homeostatic expan-
sion and acquire a memory-like phenotype (CD44high-
CD122+; see Figure 2a) similar to that of mature T cells,
which undergo homeostatic proliferation.
To test this hypothesis, we transferred thymocytes from
CBA/J donors or from recipients of allogeneic (B10.BR →
CBA/J) TCD-BMT into lethally irradiated CBA/J recipi-
ents, and assessed their proliferation 5 days later. When
we compared the transfer of CFSE-labeled thymocytes
(Figure 5a) and splenocytes (Figure 5b) from CBA/J
donors into a lethally irradiated CBA/J host, we observed
an identical slow homeostatic proliferation (with a cell
cycle longer than 24 hours) in both cell populations. This
was true for both CD4+ and CD8+ T cells, and we did not
detect any CD4+CD8+ double-positive
cells in recipients of thymocytes. All
slowly proliferating CD4+ and CD8+ thy-
mocytes had upregulated CD44+ expres-
sion, which is consistent with homeo-
static proliferation (data not shown).
These results demonstrated that thymo-
cytes can undergo homeostatic prolifer-
ation in a lymphopenic environment.
We then performed similar experi-
ments with CFSE-labeled thymocytes
and purified splenic T cells from recip-
ients of allogeneic (B10.BR → CBA/J)
TCD-BMT transferred into a lethally
irradiated CBA/J host (Figure 5, c and
d). We found that both populations
could undergo homeostatic prolifera-
tion, although we noted a second rap-
idly proliferating population among
transferred thymocytes. As expected for
homeostatically proliferating cells, we
observed increased expression of CD44
and CD122 in the slow-proliferating
populations of transferred thymocytes
(data not shown). When we compared
the two rapid- and slow-proliferating
populations of thymocytes with the
proliferation kinetics of syngeneic or allogeneic T cells
transferred into lethally irradiated recipients, we noted
that the rapidly proliferating thymocytes had the same
proliferation pattern as allogeneic T cells (Figure 5e),
whereas the slowly proliferating thymocytes had pro-
liferation kinetics similar to those of syngeneic T cells.
These rapidly proliferating thymocytes could represent
de novo–generated alloreactive thymocytes or mature
alloreactive T cells that had been transferred with the
TCD allograft and had invaded the thymus.
We conclude from these studies that thymocytes have
a capacity to undergo homeostatic expansion similar to
that of splenic T cells in lymphopenic lethally irradiated
syngeneic or allogeneic recipients. These data suggest
that RTEs in a lymphopenic recipient of allogeneic BMT
could acquire a memory-like phenotype and undergo
homeostatic proliferation, which could explain the pre-
dominance of donor-derived memory-like T cells even in
recipients of purified donor hematopoietic stem cells.
We also assessed the effects of IL-7 administration on
the homeostatic proliferation of CFSE-labeled thymo-
cytes transferred into lethally irradiated syngeneic recip-
ients. Four days after transfer, we observed an increased
fraction of slowly proliferating CD4+ and CD8+ thymo-
cytes in the IL-7–treated recipients (data not shown).
These results provide further evidence that IL-7 adminis-
tration can stimulate homeostatic proliferation of RTEs.
IL-7 administration enhances proliferation of donor-derived
memory-like peripheral T cells after allogeneic BMT. To fur-
ther analyze the effects of IL-7 administration on
peripheral T cell reconstitution in recipients of allo-
geneic BMT, we assessed the fraction of peripheral
Figure 5
De novo–generated T cells undergo homeostatic expansion in the recipient of an allo-
geneic BMT. (a and b) CFSE-labeled thymocytes (Thy) (a) and splenocytes (Spl) (b)
(107 each) from syngeneic donors (Syn) were transferred into lethally irradiated CBA/J
recipients. On day 5, splenocytes from the recipients were harvested and stained with
anti-CD4 and -CD8 antibodies for flow cytometric analysis. (c–e) Lethally irradiated
CBA/J mice were transplanted with B10.BR TCD-BM and sacrificed on day 28 after
allogeneic BMT. Thymocytes (c) and splenic T cells (d) were harvested, pooled, and
labeled with CFSE, and 107 cells were infused into irradiated CBA/J mice. On day 5,
splenocytes from the recipients were harvested and stained with anti-CD4 and -CD8
antibodies for flow cytometric analysis. Infusion with CFSE-labeled B10.BR splenic T
cells was performed as the allogeneic control (e). CBA, CBA/J.
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donor T cells in S/G2/M phase and found a significant
increase in IL-7–treated recipients (Figure 6a). These
data suggest that IL-7 has a proliferative effect on
peripheral T cells after allogeneic BMT. This prolifera-
tive effect of posttransplant IL-7 administration affect-
ed mostly memory-like T cells, as demonstrated with
pulse-chase BrdU labeling studies (Figure 6b). We fur-
ther assessed the specific effects of IL-7 administration
on homeostatic proliferation of donor T cells and
found an increase in the number of cell divisions of
CD4+ and CD8+ T cells in lethally irradiated syngeneic
recipients (Figure 6c). In IL-7–treated allogeneic recip-
ients, we observed a remarkable increase in nonallore-
active slowly proliferating CD8+ T cells, whereas IL-7
administration (again) did not increase the prolifera-
tion of the alloreactive cells (Figure 6d). When we deter-
mined the potential to secrete IFN-γ, we found, as
expected, that only fast-dividing alloreactive T cells
demonstrated increased IFN-γ secretion upon a short
stimulation with PMA-ionomycin (Figure 6e). IL-7
Figure 6
Posttransplant IL-7 administration increases the proliferation of nonalloreactive donor T cells in recipients of allogeneic BMT. (a) Lethally irra-
diated CBA/J recipients were transplanted with B10.BR TCD-BM (5 × 106) and received 10 µg/day IL-7 or PBS (control) on days 21–27. Ani-
mals were sacrificed on day 28 and splenocytes were stained with cell surface antibodies (anti-CD4, -CD8, and -Ly9.1), followed by fixation,
permeabilization, and intracellular staining with 7-AAD for cell cycle analysis. The values shown represent the mean percentage ± SEM of donor
CD4+ or CD8+ T cells in S/G2/M phase with P values comparing IL-7–treated with PBS-treated groups (four mice per group). *P < 0.05. (b)
Mice were transplanted as described in a, and BrdU was added to their drinking water at a concentration of 0.8 mg/ml on days 15–33 after
allogeneic BMT. The mice also received 1 µg/day IL-7 or PBS (control) on days 15–33. Splenocytes were harvested at day 33 and stained with
anti-CD4, CD8, -CD44, and -BrdU antibodies. The values shown represent the mean percentage ± SEM of donor naive or memory CD8+ T
cells that are BrdU+, with P values comparing IL-7–treated with PBS-treated groups (four mice per group). (c and d) Sublethally irradiated B6
(Ly5.1+) (syngeneic) or C3FeB6F1 (allogeneic) recipients were infused with CFSE-labeled B6 purified T cells (2 × 107). The recipients received
10 µg/day IL-7 or PBS (control) on days 0–3. On day 3, splenocytes were harvested and stained with anti-CD4 and anti-CD8 antibodies for
flow cytometric analysis. Results shown are representative of three duplicate experiments. (e) Splenocytes were harvested from C3FeB6F1
(allogeneic) recipients as in d, and incubated with PMA (10 ng/ml) and ionomycin (2 µM) for 5 hours. Brefeldin A was added during the last
3 hours to inhibit IFN-γ secretion. Cells were harvested and stained with anti-CD4 and anti-CD8 antibodies, then washed, fixed, permeabi-
lized, and stained intracellularly with anti–IFN-γ antibody.
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administration to the recipients of CFSE-labeled T cells
did not affect IFN-γ secretion by alloreactive T cells.
IL-7 administration decreases peripheral T cell apoptosis in
middle-aged recipients of allogeneic BMT. To test a possible
antiapoptotic effect of IL-7 on peripheral T cell recon-
stitution after allogeneic BMT, we assessed the number
of apoptotic splenic T cells in young (3-month-old) and
middle-aged (9-month-old) allogeneic recipients (Fig-
ure 7, a and b). We found an increased number of apop-
totic CD4+ and CD8+ T cells in middle-aged (but not
young) recipients of allogeneic BMT that was signifi-
cantly decreased by IL-7 administration. We determined
Bcl-2 expression levels by flow cytometry and found a
decrease in Bcl-2+ cells in peripheral T cells of allogene-
ic BMT recipients compared with normal animals, espe-
cially in middle-aged recipients. However, we could not
detect a significant increase in Bcl-2+ T cells in IL-7–
treated middle-aged recipients of allogeneic BMT.
Discussion
The majority of donor-derived T cells in the first weeks
(mouse) or months (man) after allogeneic HSCT have
a memory-like phenotype, and this has been interpret-
ed previously as evidence for a predominance of anti-
gen-driven peripheral expansion of mature T cells from
the allograft and a deficit in thymic output in the post-
transplant period (14, 15). A number of studies meas-
uring RTEs by TCR rearrangement excision circles
(TRECs) have questioned the lack of posttransplant
thymic function and were able to demonstrate signifi-
cant thymic output even in older recipients of allo-
geneic HSCT (46–49). Murine studies have demon-
strated that aged recipients of T cell–depleted BMT
display normal thymic subsets, appropriate negative
selection, and significant thymic T cell output (50% of
the thymic output of young recipients) (17).
Our results regarding the predominance of memory-
like donor T cells after transplantation of purified
hematopoietic stem cells challenge the hypothesis that
memory-like donor T cells during posttransplant recon-
stitution are being generated exclusively by the expan-
sion of mature T cells in the allograft. Moreover, our
data are in agreement with human studies regarding T
cell reconstitution following an allogeneic peripheral
blood stem cell transplant with CD34+-selected cells,
which demonstrated that most CD4+ T cells in the post-
transplant period expressed CD45RO (50).
Our data suggest that the homeostatic expansion of
peripheral T cells in a lymphopenic recipient involves
both thymic emigrants and nonalloreactive T cells in
the allograft and has the characteristics of homeostat-
ic expansion (slow proliferation kinetics and partially
activated cell surface antigen pattern) instead of classic
antigen-driven T cell proliferation (with rapid prolifer-
ation and full activated cell surface antigen pattern).
In agreement with our findings that RTEs can under-
go homeostatic proliferation, Le Campion et al. (51) have
demonstrated recently that RTEs in neonatal mice
undergo homeostatic proliferation. Interestingly, neo-
natal RTEs entering into the periphery of a neonatal
mouse maintained their naive phenotype during prolif-
eration, whereas RTEs that exited from a neonatal
thymic graft in an adult mouse acquired an activated
phenotype during homeostatic proliferation in the adult
lymphoid environment.
Goldrath et al. showed that the memory phenotype
(CD44+CD122+Ly6C+) acquired by naive CD8+ T cells
during homeostatic-driven proliferation in sublethally
irradiated syngeneic hosts was transient, and naive T
cells started to accumulate around 3 weeks after trans-
fer of spleen and lymph node cells (52). This was
explained as the reversion of memory to naive pheno-
type by homeostatic CD8+ T cells. However, several
studies have suggested that this reversal does not occur,
and that the increase of naive T cells over time is due to
de novo T cell development in the thymus (53–55). This
would suggest that homeostasis-driven proliferation
will replete only the memory T cell pool, and thy-
mopoiesis is required for reconstitution of the naive T
cell pool. We hypothesize that one reason for the delay
in reconstitution of the naive T cell pool is related to
the conversion of RTEs to memory-like T cells, which
will then undergo homeostatic proliferation until the
total T cell pool has been repleted.
Figure 7
Posttransplant IL-7 administration decreases apoptotic T cells in 
9-month-old recipients of allogeneic BMT. (a–c) CBA/J mice (3
months or 9 months old) were transplanted as described in Figure 1
without the addition of T cells. All recipients received 10 µg/day IL-7
or PBS (control) by intraperitoneal injection from day 21 to day 27.
Animals were sacrificed on day 28, and the percentage of donor-
derived apoptotic T cells was determined by flow cytometric analysis
using annexin V and anti-Ly9.1, -CD4, and -CD8 antibodies. Repre-
sentative FACS profiles from control and IL-7–treated middle-aged
mice are shown in a. The numbers of annexin V–positive donor-
derived CD4+ or CD8+ T cells from normal B10.BR mice and young
and middle-aged allogeneic BMT recipients are shown in b and c,
respectively. Values represent percentage of apoptotic cells from ten
animals per group, expressed as mean ± SEM. P values represent com-
parisons between IL-7–treated and PBS-treated groups (*P < 0.05).
The Journal of Clinical Investigation | October 2003 | Volume 112 | Number 7 1105
Our data demonstrate that the expansion of alloreac-
tive and nonalloreactive T cells in allogeneic recipients
can be distinguished based upon the number of divisions
in the first days after transplant, cell size, and the acqui-
sition of a partially or fully activated cell surface pattern.
Interestingly, the early activation marker CD69 is tem-
porarily upregulated on both alloreactive and nonallore-
active T cells before the first cell division has been com-
pleted. In our studies, CD25 expression was the most
reliable activation marker for differentiation between
alloreactive and nonalloreactive donor T cell populations.
We found a greater proliferative and cytokine response in
vitro to host antigens by alloreactive (fast-dividing) cells
compared with nonalloreactive (slow-dividing) cells, and
these results confirm our hypothesis that the fast-divid-
ing population represents alloreactive T cells.
Most studies have indicated that naive T cells require
expression of their TCR and contact with the correct
restricting MHC class I or II allele for their survival
and/or homeostatic proliferation (40, 56–61). However,
some studies have argued that survival and/or homeo-
static proliferation of CD4+ T cells can occur without
matching MHC class II ligands (62–64). These studies
have been questioned because of the possibility of con-
tamination with MHC-expressing antigen-presenting
cells among the transferred CD4+ T cells (19). Seddon
and Zamoyska (65) have suggested that TCR and IL-7R
signals can drive homeostatic proliferation independ-
ently of each other, and we are currently analyzing the
requirement for IL-7 and IL-15 in this situation.
We found that posttransplant IL-7 administration in
allogeneic HSCT recipients will predominantly result in
an expansion of memory-like donor T cells. Apart from
its thymopoietic effects (23, 66, 67), IL-7 has been pro-
posed as an important regulator of lymphoid home-
ostasis (reviewed in ref. 19). In normal mice, most IL-7 is
bound to its receptor on T cells, levels of free IL-7 are low,
and T cells have to compete for the limited IL-7 supply.
However, in lymphopenic mice, levels of unbound IL-7
increase and naive T cells have increased access to IL-7
and can undergo homeostatic expansion. It is thought
that IL-7 potentiates the reactivity of the residual naive
T cells against self-ligands, which results in their differ-
entiation into effector T cells and proliferative response.
In support of this theory, IL-7 transgenic mice have an
expanded memory T cell pool (68). Our data suggest
that IL-7 administration to allogeneic BMT recipients,
in addition to its thymopoietic effects as previously
reported (23), has important extrathymic effects and can
stimulate survival and homeostatic proliferation of
RTEs and mature T cells in the periphery.
Our findings regarding the importance of homeosta-
tic proliferation for T cell reconstitution after an allo-
geneic BMT would suggest that administration of IL-15,
which is another important γc cytokine that can regu-
late CD8+ T cell homeostatic expansion (69), can
enhance posttransplant T cell reconstitution. Indeed,
we have found that IL-15 administration increased
CD8+ T cell numbers and function after allogeneic BMT
and specifically enhanced homeostatic CD8+ T cell pro-
liferation (Ö. Alpdogan, unpublished observations).
When we analyzed CFSE-labeled purified T cells at dif-
ferent timepoints after injection into lethally irradiated
recipients, we observed a decrease in IL-7Rα expression
on donor T cells transplanted into allogeneic recipients
compared with syngeneic recipients. These data suggest
that alloreactive T cells undergo rapid downmodulation
of IL-7R upon alloactivation. In addition, in a series of
mixed lymphocyte reaction (MLR) experiments with
splenic T cells from naive animals, or from recipients
with GVHD as effectors and irradiated host splenocytes
as stimulators, we saw no increase in proliferation with
the addition of IL-7 (0.5–500 ng/ml).
A recent human DNA microarray analysis of T cells
incubated with IL-2 demonstrated that IL-7Rα was the
most potently repressed (four- to fivefold) cytokine
receptor (70). This IL-2–induced decrease of IL-7R
expression was dependent on PI3K/Akt signaling. There-
fore, we hypothesize that the downregulation of IL-7Rα
on alloreactive T cells may be, at least partially, the result
of the autocrine or paracrine effects of IL-2 secretion by
these activated T cells. Interestingly, this downregulation
of IL-7Rα on a population of T cells transferred to an
allogeneic recipient occurred before the completion of
the first cell cycle, as measured by CFSE expression. In
this very early point of T cell infusion, local IL-2 concen-
trations are probably very low and difficult to determine.
On the other hand, since IL-2 is a potent stimulator of
IL-2Rα, and IL-2Rα induction and IL-7Rα repression by
IL-2 occur concomitantly as demonstrated by Xue et al.
(70), the level of IL-2Rα expression could be used as an
indirect indicator of the presence of IL-2. Only 5.4% of
CFSE-labeled alloreactive CD8+ T cells expressed IL-2Rα
when analyzed 16 hours after infusion, and the expres-
sion of IL-2Rα on alloreactive T cells gradually increased
over the course of several days. As shown in Figure 2a, 3
days after transfer of CFSE-labeled donor T cells, all fast-
proliferative T cells expressed IL-2Rα on their surface,
whereas homeostatically, slow-proliferating CD8+ T cells
did not express IL-2Rα on their surface at any timepoint
(16 hours, 40 hours, 64 hours, 88 hours, and day 7).
Taken together, these data suggest that other factors in
addition to IL-2 can contribute to the downregulation
of IL-7Rα on alloreactive T cells, especially in the early
phase after activation against alloantigens.
In addition, a study using the P14 transgenic mouse to
analyze the changes in gene expression (by DNA microar-
ray) during the differentiation of naive antigen-specific
CD8+ T cells into effector and memory T cells demon-
strated that IL-7Rα expression was diminished (2.4-fold)
during the transition from naive to effector T cells (71).
Finally, in a recent review by Schluns and Lefrancois (72)
regarding CD8+ memory T cells, it is suggested that 
IL-7R expression is downregulated on antigen-specific
effector cells, but memory T cells will re-express IL-7Rα
after antigen clearance and contraction of effector cells.
Important differences between our GVHD experiments
and those by Sinha et al. (45), which demonstrated
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increased GVHD at some donor T cell doses, are the use
of a different IL-7 preparation at a higher dose and for a
longer period of treatment. We had previously observed
that even BMT recipients generate neutralizing antibod-
ies against recombinant human IL-7, which has only 81%
homology with murine IL-7 (23). Therefore, in our exper-
iments, recipients were never treated for more than 14
days (either from day 0 to day 14 or from day 14 to day
28), whereas Sinha et al. treated recipients continuously
for 4 weeks. We are currently generating recombinant
murine IL-7 to analyze the effects of prolonged adminis-
tration of IL-7 after transplant in our mouse models.
Older recipients of allogeneic HSCT have been shown
to have a five- to tenfold higher number of apoptotic T
cells in the periphery than do healthy controls, and this
was associated with GVHD, human leukocyte antigen
disparity, time after transplant, and the expression of
Fas and Bcl-2 (73, 74). In our experiments, IL-7 admin-
istration was capable of decreasing the number of apop-
totic peripheral T cells by 50%. Although Bcl-2 levels
were significantly decreased in T cells of older recipients
compared with younger recipients (data not shown), we
observed only a small increase in Bcl-2 levels in T cells
of older IL-7–treated recipients. Therefore the protective
effect of IL-7 administration on peripheral T cells can-
not be explained by upregulation of Bcl-2, but could
involve other IL-7–induced effects on survival, such as
PI3K-dependent increased metabolic activity (75) or
induction of the transcription factor lung Kruppel-like
factor, which is required for naive T cell survival (76, 77).
The important role of homeostatic proliferation in
posttransplant T cell reconstitution could also partially
explain the differences in CD4+ versus CD8+ T cell recon-
stitution. CD8+ T cells survive better and engage faster
in homeostatic proliferation than CD4+ T cells (40, 62,
78). In addition, homeostatic expansion of CD8+ T cells
is not limited to secondary lymphoid organs and their
antigen-presenting cells (79), and does not require lig-
ands for CCR7 (80), whereas homeostatic expansion of
CD4+ T cells is limited to lymphoid organs. This
increased potential for CD8+ T cells to undergo homeo-
static proliferation could result in a better reconstitution
of CD8+ T cells than of CD4+ T cells after transplant.
In conclusion, this study demonstrates the impor-
tance of homeostatic proliferation by both mature T
cells in the allograft and de novo–generated donor T
cells for posttransplant T cell reconstitution in recipi-
ents of an allogeneic HSCT. IL-7 administration has
clinical potential to improve posttransplant immune
deficiency, because it can promote posttransplant T cell
reconstitution through its antiapoptotic and prolifer-
ative effects on thymocytes and nonalloreactive mature
T cells without stimulating alloreactive T cells.
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